1994 Volume 42 Issue Supplement4 Pages 506-512
We performed basic and clinical studies on biapenem (BIPM). The antibacterial activity of BIPM against clinical isolates was compared with that of imipenem (IPM), panipenem (PAPM), meropenem (MEPM), ceftazidime (CAZ) and piperacillin (PIPC).
MIC90 was 1.56μg/ml for Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, 100μg/ml for Coagulase-negative Staphylococcus, 25μg/ml for Pseudomonas aeruginosa. BIPM was nearly equal to IPM against S. aureus, E. coli, K. pneumoniae and E. cloacae, and superior to all reference drugs against P. aeruginosa.
BIPM 300mg was administered intravenously by 60minutes drip infusion, and mean plasma levels were 33.1, 9.0, 5.8, 2.4, 0.9μg/ml at 0, 30, 60, 120, 240minutes after d.i.v. Mean biliary levels were 4.1, 5.7, 4.5, 2.0, 0.6μg/ml at 0, 30, 60, 120, 240miniutes after d.i.v.
BIPM was administered intravenously by drip infusion to 14 patients with various infections in the field of surgery. Clinical response were excellent in 7 cases, good in 5 cases, fair in 1 case and unevaluable in 1 case, an efficacy rate of 92.3%. No side effects were noted.
